Published in final edited form as:

Neurosci Lett. 2015 August 5; 601: 30–40. doi:10.1016/j.neulet.2015.01.011.

Dendritic spine dysgenesis in Autism Related Disorders

Mary Phillips and Lucas Pozzo-Miller

Department of Neurobiology, Civitan International Research Center, The University of Alabama at Birmingham, Birmingham AL, 35294, USA

Abstract

The activity-dependent structural and functional plasticity of dendritic spines has led to the long-standing belief that these neuronal compartments are the subcellular sites of learning and memory. Of relevance to human health, central neurons in several neuropsychiatric illnesses, including autism related disorders, have atypical numbers and morphologies of dendritic spines. These so-called dendritic spine dysgeneses found in individuals with autism related disorders are consistently replicated in experimental mouse models. Dendritic spine dysgenesis reflects the underlying synaptopathology that drives clinically relevant behavioral deficits in experimental mouse models, providing a platform for testing new therapeutic approaches. By examining molecular signaling pathways, synaptic deficits, and spine dysgenesis in experimental mouse models of autism related disorders we find strong evidence for mTOR to be a critical point of convergence and promising therapeutic target.

Keywords

mTOR; mGluR; TrkB; Fragile X; Rett syndrome; MeCP2; intellectual disability

Introduction

As Santiago Ramón y Cajal began his work describing the fine structure of nervous cells in the late nineteenth century, he noticed that many of the cells "appear bristling with thorns [*puntas*] or short spines [*espinas*]" [1], and he envisioned that these protrusions provided a source of functional connectivity between neurons [2, 3]. Though Sherrington provided the concept of the synapse soon thereafter [4], it was not until the development of electron microscopy in the 1950's and confocal fluorescence microscopy in the 1980's that spines were confirmed as an important structural component of the synapse. The functional connectivity envisioned by Cajal has been validated and it is now well-established that spines, located on the dendrites of most neurons, are the postsynaptic sites of the majority of excitatory synapses in the brain where they receive input from glutamatergic axons [5]. The

Correspondence: Lucas Pozzo-Miller, PhD, Department of Neurobiology, SHEL-1002, The University of Alabama at Birmingham, 1825 University Blvd., Birmingham, AL 35294-2182, USA, phone: +1.205.975.4659, fax: +1.205.934.6571, lucaspm@uab.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors do not have competing financial interests

ability of the dendrite to add new spines, change spine morphology, and remove spines in response to synaptic activity has led to the wide-held belief that dendritic spines are the center for synaptic plasticity, and therefore a cellular correlate to learning and memory [6]. In support of this view, many neuropsychiatric disorders, including autism with the high comorbidity of intellectual disability (ID) [7–9], present with atypical numbers and structure of dendritic spines, a cellular pathology termed “spine dysgenesis” [10]. We will first briefly describe the development, structure, and function of typical dendritic spines, and progress to detail evidence for spine dysgenesis in autism related disorders (ARDs), tracing the commonalities in dysgenesis from disorders involving entire chromosomes to those caused by single gene mutations.

Dendritic spines: history, functions, structural types, and development

In the developing brain, dendrites first develop devoid of spines and synapses. Dynamic, finger-like protrusions called filopodia begin to project from dendrites during the synaptogenesis period and have the ability to form nascent synapses with nearby axons [11]. Filopodia are highly mobile, extending and retracting to form synapses on the dendritic shaft or on spine-like protrusions that may develop into fully functioning spines [12, 13]. One leading hypothesis is that filopodia recruit axons to form synapses, though the exact mechanism of synaptogenesis during development is still under investigation and may include multiple modalities. As development continues, filopodia give way to dendritic spines, though increased densities of filopodia-like structures are seen in some ARDs, as will be discussed below [14]. Dendritic spines formed during early postnatal life undergo pruning, which eliminates roughly 50% of the synapses/spines [15, 16]. Therefore, the density of dendritic spines is dynamic and determined by neurodevelopmental stage (Figure 1).

Dendritic spines in the mature brain are typically less than 3µm in length, consist of a spherical head (0.5–1.5µm) that serves as a biochemical compartment and is connected to the parent dendrite by a thin neck (<0.5µm in diameter) thought to function as a diffusional barrier for intracellular organelles, as well as signaling ions and molecules. Excitatory synapses form on the head of the spine where the postsynaptic density acts as scaffolding for neurotransmitter receptors and signaling proteins, which includes α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and *N*-methyl-D-aspartate (NMDA) glutamate receptors. The morphology of the spines can vary in overall length, shape of the head, and length of the neck as well as in receptor ratios and diffusional properties. In frozen snapshots of a likely dynamic morphology, three main classes of spines have been described: stubby spines without an obvious neck, mushroom spines with a large head and a thin neck, and thin spines with a small head connected to the dendritic shaft by a long thin neck (Figure 1) [17]. Spine morphology has been demonstrated to contribute or be related to synaptic transmission [18], synapse formation, spine stability [19], and Ca²⁺ diffusion from the spine head to the parent dendrite [20, 21]. In addition, a positive correlation has been found between spine head size, the ratio of AMPA/NMDA receptors [22], and synaptic strength [23, 24]. These correlations provide strong evidence that the morphology of dendritic spines relates closely to the function of the synapses they belong to.

Even in a mature brain, the structure of spines is plastic and able to change both in size and shape in response to synaptic activity, and these changes can persist for prolonged periods of time. The induction of long-term potentiation (LTP) causes spine enlargement in the hippocampus [25–27] and the cortex [28]. In addition to increasing spine head volume, LTP-inducing stimuli also increase the width of the spine neck and decreases its length [29]. Conversely, the induction of long-term depression (LTD) causes a decrease in spine head volume in the hippocampus [30, 31]. Using two-photon uncaging of glutamate in combination with time-lapse two-photon imaging, Matsuzaki and colleagues showed enlargement of spines in response to induction of LTP, as well as higher levels of AMPA receptors in the postsynaptic density of potentiated spines, and that these changes depend on initial pre-LTP spine morphology. Though transient increases in size were similar in most spines, long-term changes were sustained more often in the smaller spines, leading the authors to interpret that the structure of the smaller spines led to a elevated intrinsic propensity for LTP [32]. These results support previous studies that observed individual spines *in vivo* over lengthy time spans (weeks to months) and found that smaller spines are particularly more labile [33], while larger spines may be more dominant functionally, but markedly less plastic and may remain morphologically resilient for the animal's entire adult life [34]. Further work demonstrated that both small and large spines had similar initial increases in $[Ca^{2+}]_i$ following stimulation, but larger spines with thicker necks allowed Ca^{2+} to diffuse to the parent dendrite with less diffusional delay. Ca^{2+} in smaller spines became trapped in the head, resulting in a prolonged increase in $[Ca^{2+}]_i$ localized to the head both *in vitro* [21] and *in vivo* [28]. While these studies suggest that morphological differences contribute to a spine's response to LTP-inducing stimuli through diffusional properties, it should be noted that other groups have found neck diffusion to be greatly influenced by pre- and post-synaptic activity and depolarization [35, 36]. Though the exact relationship between spine morphology and activity-induced plasticity is still under debate, colloquially the larger, more stable, mushroom and stubby spines are referred to as “memory spines” [33], where as thin spines have been dubbed the “learning spines” for their enhanced ability to undergo structural changes [19, 33, 37]. The plastic nature of dendritic spines and the role of spine morphology in synaptic signaling have led to the hypothesis that dendritic spines are a fundamental component of learning and memory.

Spine dysgenesis in autism related disorders

Spine dysgenesis has been described in autopsy brains of several ARDs, their genetic causes ranging from hundreds of affected genes to one, with their pervasiveness relating to both severity and number of clinical symptoms. By examining common clinical phenotypes correlated to spine and synaptic abnormalities between the disorders, we can work to recognize causalities in dysgenesis and identify potential targets for therapeutic intervention.

Down syndrome

Down syndrome (DS) is the most common genetic disorder associated with ID affecting 500,000 Americans. Cognitive defects in those afflicted with DS include delayed speech and language development, and impairments in spatial and long-term memory. Roughly 5–10% of individuals with DS meet the diagnosis criteria for autism spectrum disorder [38–40],

though diagnosis can be difficult in patients with severe ID. Most cases of the disorder are caused by a complete trisomy of chromosome 21 (HSA21), though there are rare cases of DS caused by partial trisomies in the long arm of HSA21, deemed the DS critical region (DSCR) [41]. Cognitive development tends to slow in children with DS and the brain undergoes a progressive postnatal degenerative process. Gross neuroanatomical phenotypes associated with DS include slightly reduced brain size and weight at birth, decreased neuronal density, aberrant neuronal morphology, and altered dendritic arborization and spines.

Dysgenesis in dendritic spines of DS patients has been found consistently in the cortex and hippocampus [10, 42–46], with the spines having atypically large heads [42]. With all previous studies having been conducted on brain samples from adults, Takashima and colleagues undertook a large-scale study comparing spine densities from patients collected during different stages of development. They provided evidence that the number of dendritic spines were typical in DS human fetuses, but that after 4 months of age spine number dipped below typical levels in the neocortex [44, 47], and that the remaining spines are morphologically longer than unaffected individuals [46]. These data suggest that dendritic spine dysgenesis in DS results from impaired spine maturation, and that synaptic pruning may be excessive [48].

The sequencing of HSA21 allowed the generation of experimental mouse models to characterize the pathophysiology of DS [49]. Of these models, Ts65Dn is most widely used and consists of a genomic fragment with 49% syntenic regions and 55% of the HSA21 gene orthologs triplicated [50, 51]. These mice have lower dendritic density, enlarged spine heads, as well as impaired hippocampal-dependent learning and memory, tested using the Morris water maze, as well as impaired LTP at excitatory hippocampal synapses [52–55], yet enhanced LTD [56, 57]. Ongoing research in DS has focused on creating mouse models with smaller selections of trisomic genes included in the DS critical region. While these models may not recapitulate all clinical features of DS individuals, they have the potential to identify the pathological role of specific genes. Located in the DSCR, regulator of calcineurin 1 (RCAN1), also known as DSCR1 [58], and Dyrk1a [59] are both implicated in DS spine phenotypes, though we will focus on RCAN1 in this review. Both knockout (KO) [60] and trisomic mouse models of RCAN1 show learning and memory deficits [61] with over-expression resulting in decreased spine density [62]. RCAN1 is a regulator of FMRP [63, 64], a protein that regulates local protein synthesis in dendrites [65–67] and transcriptionally repressed in Fragile X syndrome (FXS), a disorder characterized by spine dysgenesis [67–69] which will be discussed in further detail below.

Angelman syndrome

Angelman syndrome (AS) occurs in one out of every 12,000 births and is characterized by ID, speech impairments, ataxia, stereotypical movements, epilepsy and socialization deficits that meet the criteria for autism diagnosis [70]. The vast majority of individuals afflicted with AS have deletions in the long arm of chromosome 15 within the 15q11–13 region encoding for the *UBE3a* gene [71, 72]. *UBE3a* is genomically imprinted, causing the paternal allele to be epigenetically silenced selectively in neurons [73–79]. This portion of the

genome appears to be especially important in ARDs, as most genetic cases of autism are caused by maternal duplications of 15q11–13 [80–82], paternal deletions cause Prader-Willi syndrome (a disorder with autism comorbidity) [83], and maternal deletions cause AS which has been reported as having a comorbidity as high as ~81% for autism spectrum diagnosis [84].

Of the several mouse models of AS, the best characterized strain is the *Ube3a* KO generated by including a deletion mutation in exon 2 of the *UBE3A* gene [85–87]. The maternal deficient heterozygous mice *UBE3A*^{m-/p+} recapitulate many AS symptoms including ataxia, motor impairment, hippocampal-dependent learning and memory impairment, and about 20–30% exhibit audiogenic seizures [85, 88–90]. *UBE3A*^{m-/p+} mice also display deficiencies in hippocampal LTP [85, 91, 92] and increased metabotropic glutamate receptor (mGluR) dependent LTD [93], which correlate with lower dendritic spine density and shorter spine lengths both in the *UBE3A*^{m-/p+} mouse model [89] and an AS individual [94]. A most marked deficit in the *UBE3A*^{m-/p+} mice is the impairment in experience-dependent synaptic plasticity, revealed through monocular deprivation studies [90, 95]. These studies led to the hypothesis that the absence of UBE3A leads to the inability to modify or rearrange synapses. Recently, it has been found that UBE3A is a regulator of activity-regulated cytoskeleton-associated protein (ARC) [96], a protein instrumental in removing AMPA receptors from the postsynaptic density [97], a process required for experience-dependent synaptic plasticity [96]. Abnormal levels of ARC have also been found in Fragile X syndrome (FXS) and Tuberous Sclerosis (TS), and current research is focused on ARC's role in autism and ID [96, 98].

Rett syndrome

Rett syndrome (RTT) is an X-linked autism spectrum disorder afflicting 1 in 15,000 girls and women and is characterized by typical perinatal development until symptoms develop at 6–18 months of age [99, 100]. These symptoms include motor impairment, stereotypical movements, lack of spoken language, seizures and ID [101]. Eighty percent of RTT individuals carry mutations in *MECP2*, a gene encoding a global transcriptional regulator that binds to methylated CpG sites in the promoter regions of DNA [102–104]. Brain pathology includes reduced neuronal size but increased cell density in several brain regions [105, 106] as well as reduced dendritic arborization [107] and spine dysgenesis [108–110].

Dendritic spine dysgenesis in individuals with RTT includes not only lower spine density, but also atypical morphology resulting in a decreased proportion of mushroom-type spines in the cortex and hippocampus [107, 109, 110]. Mouse models of RTT are widely used and recapitulate many of the behavioral and anatomical abnormalities associated with the human disorder [111, 112] and additionally show impairments in both LTP and LTD [113, 114]. Commonly used strains of *Mecp2* KO mice have impaired dendritic complexity [115, 116] and lower dendritic spine density [117–120] as well as a lack of mushroom spines in cortical and hippocampal neurons [121, 122].

Interestingly, pyramidal neurons of the hippocampus of *Mecp2* KO have fewer dendritic spines only before postnatal day 15 [118, 123], suggesting that MeCP2 is necessary for dendritic spine formation during early postnatal development, but a compensatory

mechanism takes place after this period in *Mecp2* KOs. Potential mechanisms include enhanced hippocampal network activity promoting dendritic spine formation [123], deranged homeostatic plasticity stimulating spinogenesis while affecting pyramidal neuron function [124, 125], or lack of developmental synaptic pruning. Among the many genes regulated by MeCP2, *brain derived neurotrophic factor* (BDNF) may be the most prominent in RTT spine dysgenesis due to its role in neuronal growth, synapse formation and activity-dependent plasticity through the activation of tropomyosin-related kinase B (TrkB) receptors [100, 126–129] and has been shown to be lowered in RTT [112, 130–132]. Additionally, mutations in MeCP2 lead to lower expression of mGluR [133]. The combination of deficiencies in both TrkB and mGluR signaling in the dendrite may lead to insufficient activity-dependent protein translation, the potential implications of which will be discussed in further detail below.

Fragile X syndrome

Fragile X Syndrome (FXS) is the most common single-gene cause of autism and ID, afflicting approximately 1 in 4,000 males and 1 in 7,000 females [134]. Those afflicted with FXS have mild-to-severe ID, social anxiety and autistic disorders, increased incidence of epilepsy, attention problems, stereotypical movements, and sensory hypersensitivity [135–138]. The syndrome is typically caused by an expansion of ~200 CGG-repeats in the *FMR1* gene that encodes the Fragile X mental retardation protein (FMRP), which inhibits protein translation through RNA-binding. FMRP is a negative regulator of protein translation [139], many of which are localized to dendrites and dendritic spines [66, 67, 139]. Autopsies of FXS patients have shown atypical spine morphology [140–142], leading to the current hypothesis that FMRP is a key regulator of specific dendritic mRNAs and subsequently controls their translation during growth and plasticity, modulating spine morphology [7].

Reports on dendritic spine density both in human cases and in *Fmr1* KO mice are inconsistent, with some studies reporting typical density [141, 143] and others higher density [144–146], though these inconsistencies may arise from the use of animals of different ages, different brain regions, and staining and imaging methods [147]. Interestingly, Nimchinsky and colleagues described that spine density was significantly higher in *Fmr1* KO mice at 1 week of age, but this difference did not persist after the 2nd postnatal week [148]. Several live imaging studies provide evidence that the density may be within the typical range in animals older than postnatal-day 7 [149, 150]. If dendritic density is indeed elevated in younger animals, and then returns to levels comparable to those in WT mice, it may suggest that spinogenesis is increased in FXS, with excess spines being properly pruned later in development.

In contrast to the seemingly inconsistent observations on dendritic spine density, a long and tortuous spine morphology is consistently reported and considered the neuropathologic hallmark of FXS [66, 140–146, 148, 151–154]. The types of spines seen in FXS appear similar to filopodia, and many groups have described the spine morphology as ‘immature’ [66, 140–146, 148, 151–155]. In support of the hypothesis that FXS spines may exist in an immature developmentally stalled state well into adulthood, an *in vivo* 2-photon imaging study demonstrated that dendritic spines in *Fmr1* KO mice have a higher turnover rate than

those in wild type mice [156]. These atypical features of FXS spines translate to deficits in activity-dependent synaptic plasticity in *Fmr1* KO mice. Several studies reported a complete lack of LTP in the neocortex of *Fmr1* KO mice, including the visual, prefrontal and somatosensory cortices [149, 157–160]. Mixed reports regarding the state of LTP in the hippocampus can be explained by the induction protocols used: those studies using trains to elicit maximal levels of LTP reported no deficits [157, 161–163], while studies using “threshold” stimulation trains show a deficit in LTP maintenance [164, 165]. On the other hand, *Fmr1* KO mice show elevated mGluR-dependent LTD [151, 166, 167], which led to the *mGluR theory of Fragile X*: the primary defect in FXS is a functional deficiency in circuit plasticity explained by elevated mGluR signaling that influences structural and functional plasticity [168, 169].

Tuberous Sclerosis

Tuberous Sclerosis (TS) is a genetic ARD characterized by the formation of hamartomas in multiple organ systems, and affects 1 in 6,000 individuals [170]. Eighty five percent of those with TS have central nervous system complications including epilepsy, cognitive impairment, and behavioral problems [171]. The comorbidity of autism diagnosis and TS is 29% [172, 173], though more than 50% of TS patients report some autism-like features [174]. TS results from inactivating mutations in either *TSC1* or *TSC2* encoding for either hamartin or tuberin, respectively [175, 176]. These proteins bind together to form a functional heterodimer [177], working in concert as an inhibitor of the small G-protein Rheb, the key activator of mammalian target of rapamycin (mTOR) [178–181]. Thus, a mutation in either gene causes the same result: increased activity of mTOR. The discovery that the mTOR pathway is heightened in TS and the tumors TS patients develop led to the implication of the TSC2:TSC1 complex as a tumor suppressor and mTOR as a key player in tumorigenesis [182]. Furthermore, there is increasing evidence that this pathway may also be considerably involved in neuronal synaptic plasticity [183–188].

Mouse models of TS have all consistently shown impairments in hippocampal-dependent behavior and synaptic plasticity, such as impaired early-phase LTP [189, 190], and impaired mGluR-dependent LTD [191–194]. Behavioral studies have demonstrated impaired hippocampal-dependent learning in assays such as the Morris water maze, radial maze, and contextual fear conditioning [189, 190, 192, 193, 195–197], as well as impaired social interactions [198]. While these data suggest that dysgenesis of dendritic spines may occur in TS, the study of dendritic spines in TS mouse models has provided somewhat conflicting results. Either Cre-mediated *Tsc1* or *Tsc2* gene deletion in dissociated neuronal cultures from immature mice (embryonic-day 20 or postnatal-day 3) resulted in fewer dendritic spines, and most of them had an immature filopodia-like morphology [183, 199]. However, dendritic spine density was not affected when *Tsc1* was deleted *in vivo* by virus-induced Cre expression in floxed *Tsc1* mice between the 2nd and 3rd postnatal week [192]. Consistently, dendritic spine density and morphology were not affected in 3-week old *Tsc2* heterozygous mice, and after conditional deletion of *Tsc1* mice, though spine density is higher at 1-month of age [200]. Since overproduced dendritic spines are pruned between the 2nd and 3rd postnatal week of life [201], the seemingly conflicting results above could reflect an initial deficit in spinogenesis followed by impaired spine pruning, which results in higher spine

densities in 1-month old mice. In support of potential pharmacological therapies, the mTOR inhibitor rapamycin normalizes dendritic spine density in 3-week old *Tsc2* heterozygous mice [200]. Rapamycin did not affect dendritic spine density in younger *Tsc2* heterozygous mice [199], which further supports the notion intact mTOR signaling is required for dendritic spine maturation after the initial spinogenic period, i.e. during activity-dependent pruning and/or morphological maturation.

mTOR: a convergence point of spine dysgenesis and synaptopathologies in ASD

Dysgenesis of dendritic spines occurs in the majority of individuals afflicted with ARDs, as well as in most experimental mouse models of these syndromes. It would therefore follow that there must be a converging deregulated molecular pathway downstream of the affected genes and upstream of dendritic spine formation and maturation. Identifying this pathway will not only define a causal common denominator in autism-spectrum disorders, but also open new therapeutic opportunities for these devastating conditions.

The Ras/ERK and PI3K/mTOR pathways, which regulate protein translation in dendrites near excitatory synapses, have received the most attention as such candidate convergence points [202–205]. Together with the developmental profile of dendritic spine density and similar synaptic plasticity impairments after their experimental manipulation, the roles of Ras/ERK and PI3K/mTOR in all those processes support this hypothesis. The first indications were the realization that FMRP is a repressor of dendritic protein translation, localizes to dendrites near spine synapses, and modulates elements directly downstream of the Ras/ERK and PI3K/mTOR pathways [165]. Extensive work has demonstrated that key components of these signaling pathways are affected in all the ARDs discussed above (Figure 2). For example, RCAN1 (located in the DS critical region) interacts with FMRP, and their deregulation leads to comparable deficits in dendritic protein translation [63, 64]. The TS-affected proteins TSC1 and TSC2 are regulators of Rheb, and loss-of-function mutations in their genes result in higher activity of mTOR. ARC is translated in dendrites through the activation of the Ras/ERK pathway downstream of mGluR, and is the most affected protein by *Ube3a* deficiency in AS [96], although it is also deregulated in FXS [206] and TS [207]. The levels of mGluR and BDNF are lower in mouse models of RTT [130–132, 208, 209], which are upstream in both the Ras/ERK [210] and PI3K/mTOR pathways [211], and result in lower levels of the serine/threonine kinase Akt and mTOR in MeCP2-deficient mice [212]. Phosphatase and tensin homolog (PTEN), a protein often mutated in autistic patients [213–218], inhibits the activation of PDK by PI3K [219, 220].

Though many of the discussed ARDs affect multiple signaling pathways, the significant overlap on mTOR strongly suggests it is a critical convergence point. While mTOR activity usually increases dendritic protein translation, heightened mTOR activity in TS inhibits the synthesis of proteins necessary for stabilization of mGluR-dependent LTD [191]. These data, together with previous reports of lower mTOR levels resulting in reduced protein translation, suggest that mTOR activity levels need to be within a proper range to support activity-dependent synaptic plasticity [221]. Intriguingly, those ARDs with impaired mTOR-dependent translation (TS and RTT) show impaired LTD, whereas those with heightened

dendritic protein translation (DS, AS and FXS) display elevated LTD [56, 63, 222, 223]. In addition, there is a correlation between the magnitude of dendritic spine pruning, LTD, and dendritic protein translation: ARDs with excessive pruning (DS, FXS and perhaps AS) show heightened dendritic protein translation and LTD, whereas those with impaired pruning display lower protein translation and LTD (TS and RTT). Indeed, LTD in the hippocampus leads to dendritic spine shrinkage and subsequent spine synapse pruning [30, 31, 224, 225], and deficiencies in mGluR-LTD disrupt the elimination of spine synapses in the cerebellum [226]. Though there are many factors and pathways involved in the pruning of dendritic spines and their excitatory synapses, these correlations suggest that mTOR is a potential site of therapeutic intervention for autism-related disorders. In support of this notion, studies in both FXS and TS show alleviation of both synaptic and behavioral phenotypes after treatment of the mTOR inhibitor rapamycin [227, 228]. It is tempting to speculate that similar treatments will be effective to alleviate synaptopathologies and autistic behaviors in other ARDs.

Conclusion

Cajal once postulated, "the future will prove the great physiological role played by the dendritic spines" [229]. And indeed, it is now widely accepted that dendritic spines are the site of neuronal plasticity of excitatory synapses and the focal point for synaptopathophysiology of ARDs. Individuals and mouse models of ARDs all display spine dysgenesis, with mTOR-regulated protein translation being a critical point of convergence. Deviations from optimal levels of protein synthesis correlate with the magnitude of dendritic spine pruning and LTD in ARDs. Alleviation of heightened mTOR activity rescues both synaptic and behavioral phenotypes in FXS and TS animals. Correcting mTOR signaling levels also reversed ARD phenotypes in adult fully symptomatic mice, challenging the traditional view that genetic defects caused irreversible developmental defects [230]. More excitingly, these observations demonstrate the potential of pharmacological therapies for neurodevelopmental disorders. The list of ARDs that have been reversed in adult symptomatic mice continues to grow, and also includes RTT [231], DS [232, 233], and AS [92]. Together, these findings demonstrate the remarkable plastic nature of the brain and imply that if the causal denominator of ARDs could be found and therapeutically targeted, we may be able to allow the ARD brain to rewire itself and relieve clinical symptoms once believed to be irreversible. The analysis of correlative physiological and behavioral phenotypes and identification of the common mTOR pathway will hopefully provide such potential targets.

Acknowledgment

This work was supported by NIH grants NS-065027 and NS-40593 (to LP-M). We thank Drs. Xin Xu, Eric Miller, and Wei Li for thoughtful discussions.

References

1. Ramon Y Cajal S. Estructura de los centros nerviosos de las aves. Rev. Tri. Hist. Norm. Pat. 1888:1–10. <http://www.thescientist.com/?articles.view/articleNo/37954/title/The-Neuron-Doctrine--circa-1894/>.

2. Ramón y Cajal S. Significación fisiológica de las expansiones protoplásmicas y nerviosas de la sustancia gris. *Rev. Cienc. Med. Barc.* 1891; 22:23.
3. Ramón y Cajal S. La fine structure des centres nerveaux. the Croonian Lecture. *Proc. R. Soc. Lond.* 1894; 55:443–468.
4. Sherrington CS, Laslett EE. Observations on some spinal reflexes and the interconnection of spinal segments. *J. Physiol.* 1903; 29:58–96. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1540608&tool=pmcentrez&rendertype=abstract>. [PubMed: 16992657]
5. Bhatt DH, Zhang S, Gan W-B. Dendritic spine dynamics. *Annu. Rev. Physiol.* 2009; 71:261–282. [PubMed: 19575680]
6. Yuste R, Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. *Annu. Rev. Neurosci.* 2001:1071–1089. [PubMed: 11520928]
7. Dierssen M, Ramakers GJA. Dendritic pathology in mental retardation: from molecular genetics to neurobiology. *Genes. Brain. Behav.* 2006; 5(Suppl 2):48–60. [PubMed: 16681800]
8. Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. *Cereb. Cortex.* 2000; 10:981–991. <http://www.ncbi.nlm.nih.gov/pubmed/11007549>. [PubMed: 11007549]
9. Penzes P, Cahill ME, a Jones K, VanLeeuwen J-E, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. *Nat. Neurosci.* 2011; 14:285–293. [PubMed: 21346746]
10. Purpura DP. Spine “Dysgenesis” and Mental Retardation. *Science* (80-.). 1974; 186:1126–1128.
11. Ziv NE, Smith SJ. Evidence for a Role of Dendritic Filopodia in Synaptogenesis and Spine Formation. *Neuron.* 1996; 17:91–102. [PubMed: 8755481]
12. Dailey ME, Smith SJ. The Dynamics of Dendritic Structure in Developing Hippocampal Slices. *J. Neurosci.* 1996; 16:2983–2994. [PubMed: 8622128]
13. Fiala JC, Feinberg M, Popov V, Harris KM. Synaptogenesis Via Dendritic Filopodia in Developing Hippocampal Area CA1. *J. Neurosci.* 1998; 18:8900–8911. <http://www.jneurosci.org/content/18/21/8900.long>. [PubMed: 9786995]
14. Zuo Y, Lin A, Chang P, Gan W-B. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. *Neuron.* 2005; 46:181–189. [PubMed: 15848798]
15. De Felipe J, Marco P, a Fairén, Jones EG. Inhibitory synaptogenesis in mouse somatosensory cortex. *Cereb. Cortex.* 1997; 7:619–634. <http://www.ncbi.nlm.nih.gov/pubmed/9373018>. [PubMed: 9373018]
16. Huttenlocher PR. Morphometric study of human cerebral cortex development. *Neuropsychologia.* 1990; 28:517–527. [PubMed: 2203993]
17. Peters A, Kaiserman-Abramof IR. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. *Am. J. Anat.* 1970; 127:321–355. [PubMed: 4985058]
18. Matsuzaki M, Ellis-Davies GCR, Nemoto T, Miyashita Y, Iino M, Kasai H. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. *Nat. Neurosci.* 2001; 4:1086–1092. [PubMed: 11687814]
19. Holtmaat AJGD, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, et al. Transient and persistent dendritic spines in the neocortex in vivo. *Neuron.* 2005; 45:279–291. [PubMed: 15664179]
20. Korkotian E, Holcman D, Segal M. Dynamic regulation of spine-dendrite coupling in cultured hippocampal neurons. *Eur. J. Neurosci.* 2004; 20:2649–2663. [PubMed: 15548208]
21. Noguchi J, Masanori M, Ellis-Davies GCR, Kasai H. Spine-neck geometry determines NMDA receptor-dependent Ca²⁺ signaling in dendrites. *Neuron.* 2005; 46:609–622. [PubMed: 15944129]
22. Takumi Y, Ramírez-León V, Laake P, Rinvik E, Ottersen OP. Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. *Nat. Neurosci.* 1999; 2:618–624. [PubMed: 10409387]
23. Levenga J, Willemsen R. Perturbation of dendritic protrusions in intellectual disability. *Prog. Brain Res.* 2012; 197:153–168. [PubMed: 22541292]
24. Lee KFH, Soares C, Béïque J-C. Examining form and function of dendritic spines. *Neural Plast.* 2012; 2012:1–9.

25. Van Harrevel A, Fifkova E. Swelling of dendritic spines in the fascia dentata after stimulation of the perforant fibers as a mechanism of post-tetanic potentiation. *Exp. Neurol.* 1975; 49:736–749. [PubMed: 173566]
26. Fifková E, Van Harrevel A. Long-lasting morphological changes in dendritic spines of dentate granular cells following stimulation of the entorhinal area. *J. Neurocytol.* 1977; 6:211–230. [PubMed: 856951]
27. Park M, Salgado JM, Ostroff L, Helton TD, Robinson CG, Harris KM, et al. Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. *Neuron.* 2006; 52:817–830. [PubMed: 17145503]
28. Noguchi J, Nagaoka A, Watanabe S, Ellis-Davies GCR, Kitamura K, Kano M, et al. In vivo two-photon uncaging of glutamate revealing the structure-function relationships of dendritic spines in the neocortex of adult mice. *J. Physiol.* 2011; 589:2447–2457. [PubMed: 21486811]
29. Fifková E, Anderson CL. Stimulation-induced changes in dimensions of stalks of dendritic spines in the dentate molecular layer. *Exp. Neurol.* 1981; 74:621–627. [PubMed: 7297640]
30. Okamoto K-I, Nagai T, Miyawaki A, Hayashi Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. *Nat. Neurosci.* 2004; 7:1104–1112. [PubMed: 15361876]
31. Zhou Q, Homma KJ, Poo M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. *Neuron.* 2004; 44:749–757. [PubMed: 15572107]
32. Matsuzaki M, Honkura N, Ellis-Davies GCR, Kasai H. Structural basis of long-term potentiation in single dendritic spines. *Nature.* 2004; 429:761–766. [PubMed: 15190253]
33. Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. *Nature.* 2002; 420:788–794. [PubMed: 12490942]
34. Grutzendler J, Kasthuri N, Gan W-B. Long-term dendritic spine stability in the adult cortex. *Nature.* 2002; 420:812–816. [PubMed: 12490949]
35. Grunditz A, Holbro N, Tian L, Zuo Y, Oertner TG. Spine neck plasticity controls postsynaptic calcium signals through electrical compartmentalization. *J. Neurosci.* 2008; 28:13457–13466. [PubMed: 19074019]
36. Bloodgood BL, Sabatini BL. Neuronal activity regulates diffusion across the neck of dendritic spines. *Science.* 2005; 310:866–869. [PubMed: 16272125]
37. Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. *Trends Neurosci.* 2003; 26:360–368. [PubMed: 12850432]
38. Ghaziuddin M, Tsai L, Ghaziuddin N. Autism in Down's syndrome: presentation and diagnosis. *J. Intellect. Disabil. Res.* 1992; 36:449–456. [PubMed: 1458002]
39. Kent L, Evans J, Paul M, Sharp M. Comorbidity of autistic spectrum disorders in children with Down syndrome. *Dev. Med. Child Neurol.* 1999; 41:153–158. <http://www.ncbi.nlm.nih.gov/pubmed/10210247>. [PubMed: 10210247]
40. York A, von Fraunhofer N, Turk J, Sedgwick P. Fragile-X syndrome, Down's syndrome and autism: awareness and knowledge amongst special educators. *J. Intellect. Disabil. Res.* 1999; 43:314–324. [PubMed: 10466870]
41. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. *Nat. Rev. Genet.* 2004; 5:725–738. [PubMed: 15510164]
42. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. *J. Comp. Neurol.* 1976; 167:63–81. [PubMed: 131810]
43. Suetsugu M, Mehraein P. Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. *Acta Neuropathol.* 1980; 50:207–210. [PubMed: 6447982]
44. Takashima S, Becker LE, Armstrong DL, Chan F. Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative golgi study. *Brain Res.* 1981; 225:1–21. [PubMed: 6457667]
45. Ferrer I, Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. *Acta Neuropathol.* 1990; 79:680–685. [PubMed: 2141748]

46. Takashima S, Iida K, Mito T, Arima M. Dendritic and histochemical development and ageing in patients with Down's syndrome. *J. Intellect. Disabil. Res.* 1994
47. Takashima S, Ieshima A, Nakamura H, Becker LE. Dendrites, dementia and the down syndrome. *Brain Dev.* 1989; 11:131–133. [PubMed: 2523670]
48. Benavides-Piccione R, Ballesteros-Yáñez I, de Lagrán MM, Elston G, Estivill X, Fillat C, et al. On dendrites in Down syndrome and DS murine models: a spiny way to learn. *Prog. Neurobiol.* 2004; 74:111–126. [PubMed: 15518956]
49. Liu C, Belichenko PV, Zhang L, Fu D, Kleschevnikov AM, Baldini A, et al. Mouse models for Down syndrome-associated developmental cognitive disabilities. *Dev. Neurosci.* 2011; 33:404–413. [PubMed: 21865664]
50. Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. *Prog. Clin. Biol. Res.* 1990; 360:263–280. <http://europepmc.org/abstract/MED/2147289>. [PubMed: 2147289]
51. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behavior deficits. *Nat. Genet.* 1995; 11:177–184. [PubMed: 7550346]
52. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. *J. Neurosci.* 2004; 24:8153–8160. [PubMed: 15371516]
53. Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. *J. Comp. Neurol.* 2007; 504:329–345. [PubMed: 17663443]
54. Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC. The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. *J. Neurosci.* 2009; 29:5938–5948. [PubMed: 19420260]
55. Popov VI, Kleschevnikov AM, Klimenko OA, Stewart MG, Belichenko PV. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. *J. Comp. Neurol.* 2011; 519:1338–1354. [PubMed: 21452200]
56. Siarey RJ, Carlson EJ, Epstein CJ, Balbo, Rapoport SI, Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. *Neuropharmacology.* 1999; 38:1917–1920. <http://www.ncbi.nlm.nih.gov/pubmed/10608287>. [PubMed: 10608287]
57. Scott-McKean JJ, Costa ACS. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. *Learn. Mem.* 2011; 18:774–778. [PubMed: 22101180]
58. Davies KJA, Ermak G, Rothermel BA, Pritchard M, Heitman J, Ahnn J, et al. Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. *FASEB J.* 2007; 21:3023–3028. [PubMed: 17595344]
59. Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedj F, Janel N, et al. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. *J. Neurosci.* 2014; 34:1138–1147. [PubMed: 24453307]
60. Hoeffer CA, Dey A, Sachan N, Wong H, Patterson RJ, Shelton JM, et al. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. *J. Neurosci.* 2007; 27:13161–13172. [PubMed: 18045910]
61. Dierssen M, Arqué G, McDonald J, Andreu N, Martínez-Cué C, Flórez J, et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. *PLoS One.* 2011; 6:e17010. [PubMed: 21364922]
62. Martin KR, Corlett A, Dubach D, Mustafa T, Coleman HA, Parkington HC, et al. Over-expression of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. *Hum. Mol. Genet.* 2012; 21:3025–3041. [PubMed: 22511596]
63. Wang W, Zhu JZ, Chang KT, Min K-T. DSCR1 interacts with FMRP and is required for spine morphogenesis and local protein synthesis. *EMBO J.* 2012; 31:3655–3666. [PubMed: 22863780]

64. Chang KT, Ro H, Wang W, Min K-T. Meeting at the crossroads: common mechanisms in Fragile X and Down Syndrome. *Trends Neurosci.* 2013; 36:685–694. [PubMed: 24075449]
65. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. *Proc. Natl. Acad. Sci.* 1997; 94:5395–5400. [PubMed: 9144248]
66. Irwin SA, Galvez R, Greenough WT. Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome. *Cereb. Cortex.* 2000; 10:1038–1044. [PubMed: 11007554]
67. Waung MW, Huber KM. Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. *Curr. Opin. Neurobiol.* 2009; 19:319–326. [PubMed: 19411173]
68. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. *Nat. Rev. Neurosci.* 2005; 6:376–387. [PubMed: 15861180]
69. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. *Neuron.* 2008; 60:201–214. [PubMed: 18957214]
70. Clayton-Smith J. Angelman syndrome: a review of the clinical and genetic aspects. *J. Med. Genet.* 2003; 40:87–95. [PubMed: 12566516]
71. Kaplan LC, Wharton R, Elias E, Mandell F, Donlon T, Latt SA. Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible genetic significance. *Am. J. Med. Genet.* 1987; 28:45–53. [PubMed: 3674117]
72. Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. *Genet. Med.* 2010; 12:385–395. [PubMed: 20445456]
73. Albrecht U, Sutcliffe JS, Cattanaach BM, Beechey CV, Armstrong D, Eichele G, et al. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. *Nat. Genet.* 1997; 17:75–78. [PubMed: 9288101]
74. Jiang Y-H, Tsai T-F, Bressler J, Beaudet AL. Imprinting in Angelman and Prader-Willi syndromes. *Curr. Opin. Genet. Dev.* 1998; 8:334–342. [PubMed: 9691003]
75. Rougeulle C, Cardoso C, Fontés M, Colleaux L, Lalande M. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. *Nat. Genet.* 1998; 19:15–16. [PubMed: 9590281]
76. Runte M, Huttenhofer A, Gross S, Kiefmann M, Horsthemke B, Buiting K. The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A. *Hum. Mol. Genet.* 2001; 10:2687–2700. [PubMed: 11726556]
77. Yamasaki K. Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. *Hum. Mol. Genet.* 2003; 12:837–847. [PubMed: 12668607]
78. Runte M, Kroisel PM, Gillissen-Kaesbach G, Varon R, Horn D, Cohen MY, et al. SNURF-SNRPN and UBE3A transcript levels in patients with Angelman syndrome. *Hum. Genet.* 2004; 114:553–561. [PubMed: 15014980]
79. Landers M, Bancescu DL, Le Meur E, Rougeulle C, Glatt-Deeley H, Brannan C, et al. Regulation of the large (approximately 1000 kb) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf/Snrpn. *Nucleic Acids Res.* 2004; 32:3480–3492. [PubMed: 15226413]
80. Browne CE, Dennis NR, Maher E, Long FL, Nicholson JC, Sillibourne J, et al. Inherited interstitial duplications of proximal 15q: genotype-phenotype correlations. *Am. J. Hum. Genet.* 1997; 61:1342–1352. [PubMed: 9399882]
81. Cook EH, Lindgren V, Leventhal BL, Courchesne R, Lincoln A, Shulman C, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. *Am. J. Hum. Genet.* 1997; 60:928–934. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1712464&tool=pmcentrez&rendertype=abstract>. [PubMed: 9106540]
82. Mao R, Jalal SM, Snow K, Michels VV, Szabo SM, Babovic-Vuksanovic D. Characteristics of two cases with dup(15) (q 11.2-q 12): one of maternal and one of paternal origin. *Genet. Med.* 2000; 2:131–135. [PubMed: 11397326]
83. Dykens EM, Lee E, Roof E. Prader-Willi syndrome and autism spectrum disorders: an evolving story. *J. Neurodev. Disord.* 2011; 3:225–237. [PubMed: 21858456]
84. Trillingsgaard A, Østergaard JR. Autism in Angelman syndrome: an exploration of comorbidity. *Autism.* 2004; 8:163–174. [PubMed: 15165432]

85. Jiang Y-H, Armstrong D, Albrecht U, Atkins C, Sweatt JD, Beaudet AL. Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation. *Neuron*. 1998; 21:799–811. [PubMed: 9808466]
86. Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman Syndrome: Insights into Genomic Imprinting and Neurodevelopmental Phenotypes. *Trends Neurosci*. 2011; 34:293–303. [PubMed: 21592595]
87. Jana NR. Understanding the pathogenesis of Angelman syndrome through animal models. *Neural Plast*. 2012; 2012:710943. [PubMed: 22830052]
88. Miura K, Kishino T, Li E, Webber H, Dikkes P, Holmes GL, et al. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. *Neurobiol. Dis*. 2002; 9:149–159. [PubMed: 11895368]
89. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. *Hum. Mol. Genet*. 2008; 17:111–118. [PubMed: 17940072]
90. Yashiro K, Riday TT, Condon KH, Roberts AC, Bernardo DR, Prakash R, et al. Ube3a is required for experience-dependent maturation of the neocortex. *Nat. Neurosci*. 2009; 12:777–783. [PubMed: 19430469]
91. Weeber EJ, Jiang Y-H, Elgersma Y, Varga AW, Carrasquillo Y, Brown SE, et al. Derangements of Hippocampal Calcium/Calmodulin-Dependent Protein Kinase II in a Mouse Model for Angelman Mental Retardation Syndrome. *J. Neurosci*. 2003; 23:2634–2644. <http://www.jneurosci.org/content/23/7/2634.long>. [PubMed: 12684449]
92. van Woerden GM, Harris KD, Hojjati MR, Gustin RM, Qiu S, de Avila Freire R, et al. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. *Nat. Neurosci*. 2007; 10:280–282. [PubMed: 17259980]
93. Pignatelli M, Piccinin S, Molinaro G, Di Menna L, Rizzo B, Cannella M, et al. Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling angelman syndrome. *J. Neurosci*. 2014; 34:4558–4566. [PubMed: 24672001]
94. Jay V, Becker LE, Chan F-W, Perry TL. Puppet-like syndrome of Angelman: A pathologic and neurochemical study. *Neurology*. 1991; 41:416–416. [PubMed: 2006012]
95. Sato M, Stryker MP. Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a. *Proc. Natl. Acad. Sci. U. S. A*. 2010; 107:5611–5616. [PubMed: 20212164]
96. Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. *Cell*. 2010; 140:704–716. [PubMed: 20211139]
97. Shepherd JD, Bear MF. New views of Arc, a master regulator of synaptic plasticity. *Nat. Neurosci*. 2011; 14:279–284. [PubMed: 21278731]
98. Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell*. 2011; 146:247–261. [PubMed: 21784246]
99. Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder. *Neuroscientist*. 2004; 10:118–128. [PubMed: 15070486]
100. Chapeau C, Larimore JL, Theibert A, Pozzo-Miller L. Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. *J. Neurodev. Disord*. 2009; 1:185–196. [PubMed: 19966931]
101. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. *Neuron*. 2007; 56:422–437. [PubMed: 17988628]
102. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat. Genet*. 1999; 23:185–188. [PubMed: 10508514]
103. Percy AK, Lane JB. Rett syndrome: clinical and molecular update. *Curr. Opin. Pediatr*. 2004; 16:670–677. <http://www.ncbi.nlm.nih.gov/pubmed/15548931>. [PubMed: 15548931]

104. Chahrour M, Jung SY, Shaw C, Zhou X, Wong STC, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science*. 2008; 320:1224–1229. [PubMed: 18511691]
105. Bauman ML, Kemper TL, Arin DM. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett 's syndrome. *Neurology*. 1995; 45:1581–1586. [PubMed: 7644058]
106. Bauman ML, Kemper TL, Arin DM. Microscopic observations of the brain in Rett syndrome. *Neuropediatrics*. 1995; 26:105–108. [PubMed: 7566446]
107. Armstrong D, Dunn JK, Antalffy B, Trivedi R. Selective Dendritic Alterations in the Cortex of Rett Syndrome. *J. Neuropathol. Exp. Neurol.* 1995; 54:195–201. http://journals.lww.com/jneuropath/Abstract/1995/03000/Selective_Dendritic_Alterations_in_the_Cortex_of.6.aspx. [PubMed: 7876888]
108. Kaufmann WE, Taylor CV, Hohmann CF, Sanwal IB, Naidu S. Abnormalities in neuronal maturation in Rett syndrome neocortex: preliminary molecular correlates. *Eur. Child Adolesc. Psychiatry*. 6 Suppl. 1997; 1:75–77. <http://europepmc.org/abstract/MED/9452926>.
109. Belichenko PV, Oldfors A, Hagberg B, Dahlström A. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. *Neuroreport*. 1994; 5:1509–1513. http://journals.lww.com/neuroreport/Abstract/1994/07000/Rett_syndrome__3_D_confocal_microscopy_of_cortical.25.aspx. [PubMed: 7948850]
110. Chapleau C, Calfa GD, Lane MC, Albertson AJ, Larimore JL, Kudo S, et al. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. *Neurobiol. Dis.* 2009; 35:219–233. [PubMed: 19442733]
111. Li W, Pozzo-Miller L. Beyond Widespread Mecp2 Deletions to Model Rett Syndrome: Conditional Spatio-Temporal Knockout, Single-Point Mutations and Transgenic Rescue Mice. *Autism Open Access*. 2012; 2012:1–20.
112. Xu X, Miller EC, Pozzo-Miller L. Dendritic spine dysgenesis in Rett syndrome. *Front. Neuroanat.* 2014; 8:1–8. [PubMed: 24523676]
113. Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, Antalffy B, et al. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. *J. Neurosci.* 2006; 26:319–327. [PubMed: 16399702]
114. Asaka Y, Jugloff DGM, Zhang L, Eubanks JH, Fitzsimonds RM. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. *Neurobiol. Dis.* 2006; 21:217–227. [PubMed: 16087343]
115. Fukuda T, Itoh M, Ichikawa T, Washiyama K, Goto Y. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. *J. Neuropathol. Exp. Neurol.* 2005; 64:537–544. <http://www.ncbi.nlm.nih.gov/pubmed/15977646>. [PubMed: 15977646]
116. Nguyen MVC, Du F, Felice CA, Shan X, Nigam A, Mandel G, et al. MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. *J. Neurosci.* 2012; 32:10021–10034. [PubMed: 22815516]
117. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. *Proc. Natl. Acad. Sci. U. S. A.* 2009; 106:2029–2034. [PubMed: 19208815]
118. Chapleau C, Boggio EM, Calfa G, Percy AK, Giustetto M, Pozzo-Miller L. Hippocampal CA1 pyramidal neurons of Mecp2 mutant mice show a dendritic spine phenotype only in the presymptomatic stage. *Neural Plast.* 2012; 2012:976164. [PubMed: 22919518]
119. Landi S, Putignano E, Boggio EM, Giustetto M, Pizzorusso T, Ratto GM. The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. *Sci. Rep.* 2011; 1:45. [PubMed: 22355564]
120. Castro J, Garcia RI, Kwok S, Banerjee A, Petravic J, Woodson J, et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 2014; 111:9941–9946. [PubMed: 24958891]
121. Chao H-T, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. *Neuron*. 2007; 56:58–65. [PubMed: 17920015]

122. Baj G, Patrizio A, Montalbano A, Sciancalepore M, Tongiorgi E. Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. *Front. Cell. Neurosci.* 2014; 8:18. [PubMed: 24550777]
123. Calfa G, Percy AK, Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. *Exp. Biol. Med. (Maywood).* 2011; 236:3–19. [PubMed: 21239731]
124. Blackman MP, Djukic B, Nelson SB, Turrigiano GG. A critical and cellautonomous role for MeCP2 in synaptic scaling up. *J. Neurosci.* 2012; 32:13529–13536. [PubMed: 23015442]
125. Qiu Z, Sylwestrak EL, Lieberman DN, Zhang Y, Liu X-Y, Ghosh A. The Rett syndrome protein MeCP2 regulates synaptic scaling. *J. Neurosci.* 2012; 32:989–994. [PubMed: 22262897]
126. Poo MM. Neurotrophins as synaptic modulators. *Nat. Rev. Neurosci.* 2001; 2:24–32. [PubMed: 11253356]
127. Ohira K, Hayashi M. A new aspect of the TrkB signaling pathway in neural plasticity. *Curr. Neuropharmacol.* 2009; 7:276–285. [PubMed: 20514207]
128. Chapleau C, Pozzo-Miller L. Divergent roles of p75NTR and Trk receptors in BDNF's effects on dendritic spine density and morphology. *Neural Plast.* 2012; 2012:578057. [PubMed: 22548193]
129. Panja D, Bramham CR. BDNF mechanisms in late LTP formation: A synthesis and breakdown. *Neuropharmacology.* 2014; 76(Pt C):664–676. [PubMed: 23831365]
130. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron.* 2006; 49:341–348. [PubMed: 16446138]
131. Wang H, Chan S, Ogier M, Hellard D, Wang Q, Smith C, et al. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. *J. Neurosci.* 2006; 26:10911–10915. [PubMed: 17050729]
132. Li W, Calfa G, Larimore J, Pozzo-Miller L. Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice. *Proc. Natl. Acad. Sci. U. S. A.* 2012; 109:17087–17092. [PubMed: 23027959]
133. Zhong X, Li H, Chang Q. MeCP2 phosphorylation is required for modulating synaptic scaling through mGluR5. *J. Neurosci.* 2012; 32:12841–12847. [PubMed: 22973007]
134. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. *Clin. Genet.* 2011; 80:214–225. [PubMed: 21651511]
135. Sabaratnam M, Vroegop PG, Gangadharan SK. Epilepsy and EEG findings in 18 males with fragile X syndrome. *Seizure.* 2001; 10:60–63. [PubMed: 11181100]
136. Berry-Kravis E. Epilepsy in fragile X syndrome. *Dev. Med. Child Neurol.* 2007; 44:724–728. [PubMed: 12418611]
137. Hagerman R, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. *Pediatrics.* 2009; 123:378–390. [PubMed: 19117905]
138. Hagerman P, Stafstrom CE. Origins of epilepsy in fragile X syndrome. *Epilepsy Curr.* 2009; 9:108–112. [PubMed: 19693328]
139. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. *Annu. Rev. Pathol.* 2012; 7:219–245. [PubMed: 22017584]
140. Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure-Kamionowska M, Connell F, et al. Adult fragile X syndrome. Clinico-neuropathologic findings. *Acta Neuropathol.* 1985; 67:289–295. <http://www.ncbi.nlm.nih.gov/pubmed/4050344>. [PubMed: 4050344]
141. Hinton VJ, Brown WT, Wisniewski K, Rudelli RD. Analysis of neocortex in three males with the fragile X syndrome. *Am. J. Med. Genet.* 1991; 41:289–294. [PubMed: 1724112]
142. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. *Am. J. Med. Genet.* 2001; 98:161–167. <http://www.ncbi.nlm.nih.gov/pubmed/11223852>. [PubMed: 11223852]
143. Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. *Am. J. Med. Genet.* 2002; 111:140–146. [PubMed: 12210340]

144. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, et al. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. *Proc. Natl. Acad. Sci.* 1997; 94:5401–5404. [PubMed: 9144249]
145. Galvez R, Greenough WT. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. *Am. J. Med. Genet. A.* 2005; 135:155–160. [PubMed: 15880753]
146. McKinney BC, Grossman AW, Elisseeu NM, Greenough WT. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* 2005; 136B:98–102. [PubMed: 15892134]
147. Portera-Cailliau C. Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity? *Neuroscientist.* 2012; 18:28–44. [PubMed: 21551076]
148. Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. *J. Neurosci.* 2001; 21:5139–5146. <http://www.jneurosci.org/content/21/14/5139.abstract>. [PubMed: 11438589]
149. Meredith RM, Holmgren CD, Weidum M, Burnashev N, Mansvelder HD. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. *Neuron.* 2007; 54:627–638. [PubMed: 17521574]
150. Cruz-Martín A, Crespo M, Portera-Cailliau C. Delayed stabilization of dendritic spines in fragile X mice. *J. Neurosci.* 2010; 30:7793–7803. [PubMed: 20534828]
151. Koekkoek SKE, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJH, Maex R, et al. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. *Neuron.* 2005; 47:339–352. [PubMed: 16055059]
152. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 2005; 102:11557–11562. [PubMed: 16076950]
153. Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. *Mol. Cell. Neurosci.* 2006; 32:37–48. [PubMed: 16631377]
154. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J. Med. Genet.* 2009; 46:94–102. [PubMed: 18835858]
155. Pop AS, Levenga J, de Esch CEF, Buijsen RAM, Nieuwenhuizen IM, Li T, et al. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. *Psychopharmacology (Berl).* 2014; 231:1227–1235. [PubMed: 23254376]
156. Pan F, Aldridge GM, Greenough WT, Gan W-B. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 2010; 107:17768–17773. [PubMed: 20861447]
157. Li J, Pelletier MR, Perez Velazquez J-L, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. *Mol. Cell. Neurosci.* 2002; 19:138–151. [PubMed: 11860268]
158. Zhao M-G, Toyoda H, Ko SW, Ding H-K, Wu L-J, Zhuo M. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. *J. Neurosci.* 2005; 25:7385–7392. [PubMed: 16093389]
159. Desai NS, Casimiro TM, Gruber SM, Vanderklish PW. Early postnatal plasticity in neocortex of Fmr1 knockout mice. *J. Neurophysiol.* 2006; 96:1734–1745. [PubMed: 16823030]
160. Wilson BM, Cox CL. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. *Proc. Natl. Acad. Sci. U. S. A.* 2007; 104:2454–2459. [PubMed: 17287348]
161. Godfraind JM, Reyniers E, De Boule K, D’Hooge R, De Deyn PP, Bakker CE, et al. Long-term potentiation in the hippocampus of fragile X knockout mice. *Am. J. Med. Genet.* 1996; 64:246–251. [PubMed: 8844057]

162. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. *Neuroscience*. 1999; 94:185–192. [PubMed: 10613508]
163. Larson J, Jessen RE, Kim D, Fine A-KS, du Hoffmann J. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. *J. Neurosci*. 2005; 25:9460–9469. [PubMed: 16221856]
164. Lauterborn JC, Rex CS, Kramár E, Chen LY, Pandeyarajan V, Lynch G, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. *J. Neurosci*. 2007; 27:10685–10694. [PubMed: 17913902]
165. Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. *J. Neurosci*. 2008; 28:7847–7862. [PubMed: 18667617]
166. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc. Natl. Acad. Sci. U. S. A.* 2002; 99:7746–7750. [PubMed: 12032354]
167. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. *Neuron*. 2006; 51:441–454. [PubMed: 16908410]
168. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci*. 2004; 27:370–377. [PubMed: 15219735]
169. Dölen G, Bear MF. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. *J. Physiol*. 2008; 586:1503–1508. [PubMed: 18202092]
170. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. *Ann. N. Y. Acad. Sci.* 1991; 615:125–127. <http://www.ncbi.nlm.nih.gov/pubmed/2039137>. [PubMed: 2039137]
171. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. *Lancet*. 2008; 372:657–668. [PubMed: 18722871]
172. Gutierrez GC, Smalley SL, Tanguay PE. Autism in tuberous sclerosis complex. *J. Autism Dev. Disord*. 1998; 28:97–103. <http://www.ncbi.nlm.nih.gov/pubmed/9586771>. [PubMed: 9586771]
173. Curatolo P, Napolioni V, Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. *J. Child Neurol*. 2010; 25:873–880. [PubMed: 20207609]
174. Hunt A, Dennis J. PSYCHIATRIC DISORDER AMONG CHILDREN WITH TUBEROUS SCLEROSIS. *Dev. Med. Child Neurol*. 2008; 29:190–198. [PubMed: 3582788]
175. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science*. 1997; 277:805–808. <http://www.ncbi.nlm.nih.gov/pubmed/9242607>. [PubMed: 9242607]
176. Kandt RS, Haines JL, Smith M, Northrup H, Gardner RJ, Short MP, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. *Nat. Genet*. 1992; 2:37–41. [PubMed: 1303246]
177. van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, et al. Interaction between hamartin and tuberlin, the TSC1 and TSC2 gene products. *Hum. Mol. Genet*. 1998; 7:1053–1057. <http://www.ncbi.nlm.nih.gov/pubmed/9580671>. [PubMed: 9580671]
178. Inoki K, Li Y, Xu T, Guan K-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev*. 2003; 17:1829–1834. [PubMed: 12869586]
179. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Rocco M, Stocker H, et al. Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2. *Mol. Cell*. 2003; 11:1457–1466. [PubMed: 12820960]
180. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous Sclerosis Complex Gene Products, Tuberlin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. *Curr. Biol*. 2003; 13:1259–1268. [PubMed: 12906785]
181. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. *Trends Biochem. Sci*. 2003; 28:573–576. [PubMed: 14607085]
182. Guertin D, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell*. 2007; 12:9–22. [PubMed: 17613433]

183. Tavazoie SF, Alvarez V, Ridenour D, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. *Nat. Neurosci.* 2005; 8:1727–1734. [PubMed: 16286931]
184. Jaworski J, Sheng M. The growing role of mTOR in neuronal development and plasticity. *Mol. Neurobiol.* 2006; 34:205–219. [PubMed: 17308353]
185. de Vries PJ, Howe CJ. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment. *Trends Mol. Med.* 2007; 13:319–326. [PubMed: 17632034]
186. Swiech L, Perycz M, Malik A, Jaworski J. Role of mTOR in physiology and pathology of the nervous system. *Biochim. Biophys. Acta.* 2008; 1784:116–132. [PubMed: 17913600]
187. Richter JD, Klann E. Making synaptic plasticity and memory last: mechanisms of translational regulation. *Genes Dev.* 2009; 23:1–11. [PubMed: 19136621]
188. Orlova KA, Crino PB. The tuberous sclerosis complex. *Ann. N. Y. Acad. Sci.* 2010; 1184:87–105. [PubMed: 20146692]
189. Zeng L-H, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC, et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. *Neurobiol. Dis.* 2007; 28:184–196. [PubMed: 17714952]
190. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. *Nat. Med.* 2008; 14:843–848. [PubMed: 18568033]
191. Auerbach BD, Bear MF. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. *J. Neurophysiol.* 2010; 104:1047–1051. [PubMed: 20554840]
192. Bateup HS, Takasaki KT, Saulnier JL, Deneffio CL, Sabatini BL. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. *J. Neurosci.* 2011; 31:8862–8869. [PubMed: 21677170]
193. Chévere-Torres I, Kaphzan H, Bhattacharya A, Kang A, Maki JM, Gambello MJ, et al. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the RG mouse model of tuberous sclerosis complex. *Neurobiol. Dis.* 2012; 45:1101–1110. [PubMed: 22198573]
194. Kirschstein T. Synaptic plasticity and learning in animal models of tuberous sclerosis complex. *Neural Plast.* 2012; 2012:279834. [PubMed: 22848848]
195. Goorden SMI, van Woerden GM, van der Weerd L, Cheadle JP, Elgersma Y. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. *Ann. Neurol.* 2007; 62:648–655. [PubMed: 18067135]
196. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. *Nature.* 2011; 480:63–68. [PubMed: 22113615]
197. Ehninger D, Silva AJ. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. *Behav. Genet.* 2011; 41:357–363. [PubMed: 20882401]
198. Chévere-Torres I, Maki JM, Santini E, Klann E. Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin. *Neurobiol. Dis.* 2012; 45:156–164. [PubMed: 21827857]
199. Yasuda S, Sugiura H, Katsurabayashi S, Shimada T, Tanaka H, Takasaki K, et al. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex. *Sci. Rep.* 2014; 4:5155. [PubMed: 24889507]
200. Tang G, Gudsnek K, Kuo S-H, Cotrina ML, Rosoklija G, Sosunov A, et al. Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits. *Neuron.* 2014; 83:1131–1143. [PubMed: 25155956]
201. Zuo Y, Yang G, Kwon E, Gan W-B. Long-term sensory deprivation prevents dendritic spine loss in primary somatosensory cortex. *Nature.* 2005; 436:261–265. [PubMed: 16015331]
202. Kelleher RJ, Bear MF. The autistic neuron: troubled translation? *Cell.* 2008; 135:401–406. [PubMed: 18984149]
203. Troca-Marín JA, Alves-Sampaio A, Montesinos ML. Deregulated mTOR-mediated translation in intellectual disability. *Prog. Neurobiol.* 2012; 96:268–282. [PubMed: 22285767]

204. Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. *Nat. Neurosci.* 2013; 16:1537–1543. [PubMed: 24165680]
205. Bowling H, Klann E. Shaping Dendritic Spines in Autism Spectrum Disorder: mTORC1-Dependent Macroautophagy. *Neuron.* 2014; 83:994–996. [PubMed: 25189205]
206. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. *Cell.* 2003; 112:317–327. <http://www.ncbi.nlm.nih.gov/pubmed/12581522>. [PubMed: 12581522]
207. Bateup HS, a Johnson C, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. *Neuron.* 2013; 78:510–522. [PubMed: 23664616]
208. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. *J. Neurosci.* 2007; 27:10912–10917. [PubMed: 17913925]
209. Xu X, Kozikowski AP, Pozzo-Miller L. A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. *Front. Cell. Neurosci.* 2014; 8:1–9. [PubMed: 24478626]
210. Alonso M, Medina JH, Pozzo-Miller L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. *Learn. Mem.* 11:172–178. (n.d.). [PubMed: 15054132]
211. Kumar V, Zhang M-X, Swank MW, Kunz J, Wu G-Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. *J. Neurosci.* 2005; 25:11288–11299. [PubMed: 16339024]
212. Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. *Hum. Mol. Genet.* 2011; 20:1182–1196. [PubMed: 21212100]
213. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. *Am. J. Med. Genet. A.* 143A. 2007:589–593.
214. Orrico A, Galli L, Buoni S, Orsi A, Vonella G, Sorrentino V. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. *Clin. Genet.* 2009; 75:195–198. [PubMed: 18759867]
215. Varga EA, Pastore M, Prior T, Herman GE, McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet. Med.* 2009; 11:111–117. [PubMed: 19265751]
216. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res.* 2010; 3:137–141. [PubMed: 20533527]
217. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science.* 2012; 338:1619–1622. [PubMed: 23160955]
218. Hobert JA, Embacher R, Mester JL, Frazier TW, Eng C. Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. *Eur. J. Hum. Genet.* 2014; 22:273–276. [PubMed: 23695273]
219. Butler MG, Dasouki MJ, Zhou X-P, Talebizadeh Z, Brown M, Takahashi TN, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J. Med. Genet.* 2005; 42:318–321. [PubMed: 15805158]
220. Kwon C-H, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, et al. Pten regulates neuronal arborization and social interaction in mice. *Neuron.* 2006; 50:377–388. [PubMed: 16675393]
221. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. *Cold Spring Harb. Perspect. Biol.* 2012; 4

222. Troca-Marín JA, Alves-Sampaio A, Montesinos ML. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. *J. Neurosci.* 2011; 31:9445–9455. [PubMed: 21715609]
223. Iyer AM, van Scheppingen J, Milenkovic I, Anink JJ, Adle-Biassette H, Kovacs GG, et al. mTOR Hyperactivation in down syndrome hippocampus appears early during development. *J. Neuropathol. Exp. Neurol.* 2014; 73:671–683. [PubMed: 24918639]
224. Bastrikova N, Gardner GA, Reece JM, Jeromin A, Dudek SM. Synapse elimination accompanies functional plasticity in hippocampal neurons. *Proc. Natl. Acad. Sci. U. S. A.* 2008; 105:3123–3127. [PubMed: 18287055]
225. Shinoda Y, Tanaka T, Tominaga-Yoshino K, Ogura A. Persistent synapse loss induced by repetitive LTD in developing rat hippocampal neurons. *PLoS One.* 2010; 5:e10390. [PubMed: 20436928]
226. Watanabe M, Kano M. Climbing fiber synapse elimination in cerebellar Purkinje cells. *Eur. J. Neurosci.* 2011; 34:1697–1710. [PubMed: 22103426]
227. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. *J. Neurosci.* 2008; 28:5422–5432. [PubMed: 18495876]
228. Cambiaghi M, Cursi M, Magri L, Castoldi V, Comi G, Minicucci F, et al. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. *Neuropharmacology.* 2013; 67:1–7. [PubMed: 23159330]
229. Ramón y Cajal, S. Moya, Madrid: 1904. TEXTURA DEL SISTEMA NERVIOSO DEL HOMBRE Y DE LOS VERTEBRADOS. <http://www.casadellibro.com/libro-textura-del-sistema-nervioso-del-hombre-y-de-los-vertebrados-3-v-ols/9788477539254/845754> [accessed October 02, 2014]
230. Ehninger D, Li W, Fox K, Stryker MP, Silva AJ. Reversing neurodevelopmental disorders in adults. *Neuron.* 2008; 60:950–960. [PubMed: 19109903]
231. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. *Science.* 2007; 315:1143–1147. [PubMed: 17289941]
232. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. *Nat. Neurosci.* 2007; 10:411–413. [PubMed: 17322876]
233. Rueda N, Flórez J, Martínez-Cué C. Chronic pentylentetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. *Neurosci. Lett.* 2008; 433:22–27. [PubMed: 18226451]

Figure 1. Characterization of dendritic spines in autism related disorders

Numerical density of dendritic spines during neurodevelopmental stages, and morphologies of mature spines in different ARDs. In typical subjects (grey shading), spines and synapses are formed during early development with the excess or weaker connections being selectively pruned in adolescence, after which spines are maintained during adulthood. Morphological types of spines include thin, mushroom, and stubby, filopodia-like spines are uncommon in the mature brain. Tuberous Sclerosis (purple) has a lower density during spinogenesis, is within typical levels in the pruning stage, and higher densities during maturity with normal morphology. Fragile X syndrome (blue) has higher densities until the maintenance stage has been reached, when the density lowers to typical levels and have spines that are morphologically more immature, including a higher proportion of thin and filopodia-like spines. Rett syndrome (green) has a lower density until the maintenance phase with a lower proportion of mushroom spines. There is a lack of density data in Angelman syndrome (red) for both the spinogenesis and pruning stages, but mouse models have lowered densities in the maintenance phase with more variable spine morphology. Down syndrome (brown) has lower densities after the spinogenesis phase with remaining spines having larger heads and longer necks.

Figure 2. Pathways involved in the translational regulation of “LTD proteins”

ARDs share molecular pathologies affecting a common signaling pathway involved in activity-dependent protein synthesis in distal dendrites near spine synapses. The Ras/ERK and PI3K/mTOR signaling pathways couple synaptic activation of mGluR and the BDNF TrkB receptors to protein translation that is essential to the maintenance of LTD. Mutations in several regulators of these pathways, including the genes encoding the proteins TSC1/2, FMRP, DSCR1, UBE3A, and PTEN are responsible for ARDs. Loss-of-function mutations in the gene encoding the nuclear protein MeCP2, which causes RTT, result in lower levels of mGluR and BDNF, lowering the activation of those signaling pathways in response to glutamatergic synaptic activity and activity-dependent BDNF release. While mTOR is typically an activator of protein translation through 4E-BP and S6K, pathological increases in mTOR levels repress translation of LTD-specific proteins, though the exact mechanism(s) is unknown. Selective inhibition of mTOR with rapamycin alleviates autism-related deficits in FXS and TS, providing evidence that this pathway is causal in the pathological mechanisms leading to autism.

Abbreviations: Glu: glutamate; Ras: rat sarcoma proto-oncogenic G-protein; MEK: MAPK kinase; ERK: extracellular signal-related kinase; Rheb: RAS homolog enriched in brain; Mnk: MAP kinases phosphorylate; eIF4E: Eukaryotic initiation factor 4E; 4E-BP: eukaryotic translation initiation factor 4E binding protein; S6: ribosomal protein S6; S6K:

S6 kinase; 40S: eukaryotic small ribosomal subunit; PI3K: phosphoinositide 3-kinase; PDK: phosphoinositide-dependent kinase; P: phosphate.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript